Lilly's Verzenio(R) (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
Verzenio is the first and only CDK4 & 6 inhibitor in combination with fulvestrant to achieve statistically significant improvement in overall survival
MONARCH 2 was a Phase 3 study including both pre/peri- and postmenopausal women whose cancer progresse... Biopharmaceuticals, Oncology Eli Lilly, Verzenio, abemaciclib, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Pharmaceuticals | Statistics | Study | Women